#68345
#68346
Re: Chicharros USA - bolsa internacional
Estoy por soltar las GOVX que me suben un 6% e incrementar en MICT........pero sólo por los oferings directos que han hecho........por que desde el punto de vista técnico.........como pierda los mínimos del viernes, se nos cae.
#68347
Re: Chicharros USA - bolsa internacional
AGEN
Resultados financieros el lunes de la próxima semana
AVEO
BOSTON--(BUSINESS WIRE)--Jun. 1, 2020-- AVEO Oncology (NASDAQ: AVEO) today announced that the U.S. Food and Drug Administration (FDA) accepted for filing its New Drug Application (NDA) seeking approval for tivozanib, the Company’s next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), as a treatment for relapsed or refractory renal cell carcinoma (RCC). The FDA has assigned the application standard review and a Prescription Drug User Fee Act target action date of March 31, 2021. The FDA also indicated that they do not currently plan on convening an Oncologic Drug Advisory Committee (ODAC) to discuss the application.
IMV
Resultados financieros el miércoles del próxima semana
Over the course of upcoming quarters, the Company expects to deliver the following milestones:
Resultados financieros el lunes de la próxima semana
AVEO
BOSTON--(BUSINESS WIRE)--Jun. 1, 2020-- AVEO Oncology (NASDAQ: AVEO) today announced that the U.S. Food and Drug Administration (FDA) accepted for filing its New Drug Application (NDA) seeking approval for tivozanib, the Company’s next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), as a treatment for relapsed or refractory renal cell carcinoma (RCC). The FDA has assigned the application standard review and a Prescription Drug User Fee Act target action date of March 31, 2021. The FDA also indicated that they do not currently plan on convening an Oncologic Drug Advisory Committee (ODAC) to discuss the application.
IMV
Resultados financieros el miércoles del próxima semana
Over the course of upcoming quarters, the Company expects to deliver the following milestones:
- DPX-Survivac
- Additional Phase 2 clinical results from the DLBCL combination at the American Society of Hematology (ASH) annual meeting to be held virtually on December 6, 2020
- Top line Phase 2 clinical results from the ovarian cancer trial on December 3, 2020
- Updated Phase 2 clinical results from the basket trial in Q1 2021
- DPX-COVID-19
- Initiation of Phase 1/2 clinical trial with DPX-COVID-19 in 2020
- Preliminary Phase 1/2 results in Q1 2021
IMGN
UPCOMING EVENTS
- Complete patient enrollment in SORAYA, with top-line pivotal data expected in the third quarter of 2021, and submit the biologics license application (BLA) by the end of 2021 to support potential accelerated approval in 2022.
- Complete patient enrollment in MIRASOL, with top-line data expected in the first half of 2022.
- Present mature data from the Phase 1b FORWARD II cohort evaluating mirvetuximab in combination with Avastin® (bevacizumab) in platinum agnostic, recurrent ovarian cancer at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
- Support initiation of two investigator-sponsored trials of mirvetuximab plus carboplatin, including a randomized Phase 2 study in recurrent platinum-sensitive ovarian cancer and a neo-adjuvant study.
- Enroll patients in the pivotal cohort of the 801 Phase 1/2 study of IMGN632 in frontline BPDCN patients and generate top-line data in 12 to 18 months.
- Advance the 802 Phase 1b/2 study of IMGN632 in combination with azacitidine and venetoclax in R/R and frontline AML patients and as a monotherapy in minimal residual disease positive (MRD+) AML following frontline induction therapy.
- Present updated R/R BPDCN and initial AML combination data for IMGN632 at ASH 2021.
- Complete dose escalation and move to expansion cohorts in the Phase 1 study evaluating IMGC936, with initial data anticipated by the end of 2021 or early 2022.
- Submit the investigational new drug (IND) application for IMGN151 by the end of 2021.
Un saludo y muchos aciertos
#68348
Re: Chicharros USA - bolsa internacional
SLNO
Parece que tengan ganas de marear la perdiz, si no hubiese sido viable se lo hubiesen denagado hoy mismo. Espero que en breve se lo aprueben
Parece que tengan ganas de marear la perdiz, si no hubiese sido viable se lo hubiesen denagado hoy mismo. Espero que en breve se lo aprueben
#68349
Re: Chicharros USA - bolsa internacional
SLNO
Ya se ha frenado la caída, por si alguien quiere entrar para mañana
Ya se ha frenado la caída, por si alguien quiere entrar para mañana
#68350
Re: Chicharros USA - bolsa internacional
Off Topics
Otro sector a tener en cuenta, por variar.....
COCHES ELECTRICOS
https://seekingalpha.com/news/3670328-house-democrats-to-push-electric-vehicle-legislation
WKHS, Alguien la sigue a esta bicha???? Gracias.
#68351
Re: Chicharros USA - bolsa internacional
SLNO
Bueno, no esta claro que el NASDAQ está casi en mínimo. Esperemos que mañana rebote todo
Bueno, no esta claro que el NASDAQ está casi en mínimo. Esperemos que mañana rebote todo
#68352
Re: Chicharros USA - bolsa internacional
Alex yo llevo de estas, hacen camiones y demas, pasa que perdieron un contrato millonario y les ha pasado factura y gorda...
